MHC GENES INVOLVED IN ANTIGEN PROCESSING & PRESENTATION
参与抗原加工的 MHC 基因
基本信息
- 批准号:3147887
- 负责人:
- 金额:$ 12.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1992
- 资助国家:美国
- 起止时间:1992-01-01 至 1994-12-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
T lymphocyte activation, and hence the initiation of an immune response,
requires recognition by T cell receptors of complexes consisting of peptide
fragments of foreign antigens bound to major histocompatibility complex
(MHC) molecules on the surface of antigen presenting cells (APC). Despite
the critical nature of this first step in immune recognition, little is
known about the mechanistic aspects of antigen processing, such as how the
antigen fragments are produced, and how and where within the APC they
encounter MHC molecules.
A growing body of evidence suggests that the MHC contains genes which
function in the transport of processed antigen into vesicles of the
secretory system for binding by MHC class molecules and subsequent
vesicular transport to the cell surface. The recent cloning of two MHC
genes, called HAM1 and HAM2, which are homologous to a large superfamily of
both prokaryotic and eukaryotic transporters represents a major step
towards understanding the nature of antigen processing. This proposal
deals with the structural and functional characterization of these two
genes. Two types of experiments will be done to provide formal proof of
the involvement of the HAM1 and HAM2 gene in antigen processing. First,
full length, wild type HAM1 and HAM2 cDNAs will be introduced into cell
lines carrying MHC-linked mutations that inactivate the antigen processing
pathway. Second, mice deficient in HAM1 and HAM2 expression will be
produced by introducing defective copies of these genes into embryonic stem
cells by homologous recombination, and subsequently injecting these
modified cells into mouse blastocysts. In order to further characterize
the function of the HAM1 and HAM2 gene products, antibody will be produced
to synthetic peptides derived from the deduced amino acid sequences. This
antibody will be used immunohistochemically to localize the corresponding
proteins within the cell (thus identifying the subcellular compartment
where peptide meets MHC molecule), and to aid in their purification.
Attempts will be made to reconstitute peptide transport in in vitro
systems, and to analyze the specificity of the transport process.
In addition to the above, the functional significance of two novel MHC
class II-like genes will be addressed by examining their polymorphism and
by producing antibody which would allow identification of the corresponding
gene products.
T淋巴细胞活化,从而引发免疫反应,
需要T细胞受体识别由肽组成的复合物
与主要组织相容性复合体结合的外源抗原片段
(MHC)抗原呈递细胞(APC)表面的分子。 尽管
免疫识别第一步的关键性,
了解抗原加工的机械方面,例如
抗原片段的产生,以及它们如何以及在APC内的何处产生,
遇到MHC分子。
越来越多的证据表明,MHC含有的基因,
在将加工的抗原转运到膜囊泡中的功能
用于与MHC类分子结合的分泌系统和随后的
囊泡运输到细胞表面。 最近克隆的两个MHC
基因,称为HAM1和HAM2,这是同源的一个大的超家族,
原核和真核转运蛋白都代表了
了解抗原加工的本质。 这项建议
涉及这两个的结构和功能特征,
基因. 将进行两种类型的实验,以提供正式的证据,
HAM1和HAM2基因参与抗原加工。 第一、
将全长野生型HAM1和HAM2 cDNA导入细胞
携带MHC连锁突变的细胞系,
通路 第二,HAM1和HAM2表达缺陷的小鼠将被
通过将这些基因的缺陷拷贝引入胚胎干细胞而产生
细胞通过同源重组,并随后注射这些
将修饰的细胞转化为小鼠胚泡。 为了进一步表征
HAM1和HAM2基因产物的功能,抗体将产生
衍生自推导的氨基酸序列的合成肽。 这
将使用免疫组化抗体来定位相应的
细胞内的蛋白质(从而识别亚细胞区室
其中肽与MHC分子相遇),并有助于它们的纯化。
将尝试在体外重建肽转运
系统,并分析运输过程的特殊性。
除上述外,两种新的MHC的功能意义
II类基因将通过检查它们的多态性来解决,
通过产生抗体,
基因产物
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John J. Monaco其他文献
Genomic polymorphism, recombination, and linkage disequilibrium in human major histocompatibility complex-encoded antigen-processing genes.
人类主要组织相容性复合体编码的抗原加工基因的基因组多态性、重组和连锁不平衡。
- DOI:
10.1073/pnas.89.23.11594 - 发表时间:
1992 - 期刊:
- 影响因子:11.1
- 作者:
P. M. V. Endert;M. T. Lopez;S. Patel;John J. Monaco;H. Mcdevitt - 通讯作者:
H. Mcdevitt
MHC class II region encoding proteins related to the muKidrug resistance family of transmembrane transporters
MHC Ⅱ类区域编码与跨膜转运蛋白 muKidrug 耐药家族相关的蛋白质
- DOI:
10.1038/348738a0 - 发表时间:
1990-12-27 - 期刊:
- 影响因子:48.500
- 作者:
Edward V. Deverson;Irene R. Gow;W. John Coadwell;John J. Monaco;Geoffrey W. Butcher;Jonathan C. Howard - 通讯作者:
Jonathan C. Howard
New class ll-like genes in the murine MHC
小鼠主要组织相容性复合体中的新型类 II 基因
- DOI:
10.1038/353573a0 - 发表时间:
1991-10-10 - 期刊:
- 影响因子:48.500
- 作者:
Sungae Cho;Michelle Attaya;John J. Monaco - 通讯作者:
John J. Monaco
Production of congenic Anti-Lyt-3.1 sera
- DOI:
10.1007/bf01844002 - 发表时间:
1978-12-01 - 期刊:
- 影响因子:2.900
- 作者:
Stephen C. Boos;John J. Monaco;Paul D. Gottlieb - 通讯作者:
Paul D. Gottlieb
John J. Monaco的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John J. Monaco', 18)}}的其他基金
Proteasome subunit beta5t and thymus-specific peptides in T cell selection
T 细胞选择中的蛋白酶体亚基 beta5t 和胸腺特异性肽
- 批准号:
8701462 - 财政年份:2014
- 资助金额:
$ 12.75万 - 项目类别:
Proteasome subunit beta5t and thymus-specific peptides in T cell selection
T 细胞选择中的蛋白酶体亚基 beta5t 和胸腺特异性肽
- 批准号:
8824482 - 财政年份:2014
- 资助金额:
$ 12.75万 - 项目类别:
PROTEASOME-LMP COMPLEX AND ANTIGEN PROCESSING
蛋白酶体-LMP 复合物和抗原加工
- 批准号:
2068671 - 财政年份:1993
- 资助金额:
$ 12.75万 - 项目类别:
PROTEASOME-LMP COMPLEX AND ANTIGEN PROCESSING
蛋白酶体-LMP 复合物和抗原加工
- 批准号:
2068673 - 财政年份:1993
- 资助金额:
$ 12.75万 - 项目类别:
PROTEASOME-LMP COMPLEX AND ANTIGEN PROCESSING
蛋白酶体-LMP 复合物和抗原加工
- 批准号:
2068672 - 财政年份:1993
- 资助金额:
$ 12.75万 - 项目类别:
PROTEASOME-LMP COMPLEX AND ANTIGEN PROCESSING
蛋白酶体-LMP 复合物和抗原加工
- 批准号:
3148678 - 财政年份:1993
- 资助金额:
$ 12.75万 - 项目类别:
PROTEASOME-LMP COMPLEX AND ANTIGEN PROCESSING
蛋白酶体-LMP 复合物和抗原加工
- 批准号:
2003899 - 财政年份:1993
- 资助金额:
$ 12.75万 - 项目类别:
ROLE OF THE PROTEASOME/LMP COMPLEX IN ANTIGEN PROCESSING
蛋白酶体/LMP 复合物在抗原加工中的作用
- 批准号:
3148679 - 财政年份:1993
- 资助金额:
$ 12.75万 - 项目类别:
MHC GENES INVOLVED IN ANTIGEN PROCESSING & PRESENTATION
参与抗原加工的 MHC 基因
- 批准号:
3147889 - 财政年份:1992
- 资助金额:
$ 12.75万 - 项目类别:
MHC GENES INVOLVED IN ANTIGEN PROCESSING & PRESENTATION
参与抗原加工的 MHC 基因
- 批准号:
2067654 - 财政年份:1992
- 资助金额:
$ 12.75万 - 项目类别:
相似海外基金
Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
- 批准号:
10836880 - 财政年份:2023
- 资助金额:
$ 12.75万 - 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
- 批准号:
10734324 - 财政年份:2023
- 资助金额:
$ 12.75万 - 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
- 批准号:
10740465 - 财政年份:2023
- 资助金额:
$ 12.75万 - 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
- 批准号:
23K04971 - 财政年份:2023
- 资助金额:
$ 12.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
- 批准号:
2885451 - 财政年份:2023
- 资助金额:
$ 12.75万 - 项目类别:
Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
- 批准号:
10385926 - 财政年份:2022
- 资助金额:
$ 12.75万 - 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
- 批准号:
10509043 - 财政年份:2022
- 资助金额:
$ 12.75万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10704008 - 财政年份:2022
- 资助金额:
$ 12.75万 - 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
- 批准号:
10818273 - 财政年份:2022
- 资助金额:
$ 12.75万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10349397 - 财政年份:2022
- 资助金额:
$ 12.75万 - 项目类别: